PDS Biotechnology Analyst Ratings
PDS Biotechnology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 09/20/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 08/14/2023 | 302.3% | HC Wainwright & Co. | $21 → $21 | Reiterates | Buy → Buy |
| 06/06/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 05/26/2023 | 359.77% | Oppenheimer | → $24 | Reiterates | Outperform → Outperform |
| 05/26/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 05/16/2023 | 359.77% | Oppenheimer | → $24 | Reiterates | → Outperform |
| 04/24/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/30/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 03/29/2023 | 129.89% | B. Riley Securities | → $12 | Reiterates | → Buy |
| 03/28/2023 | 302.3% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 02/28/2023 | 302.3% | HC Wainwright & Co. | → $21 | Maintains | Buy |
| 01/03/2023 | 302.3% | HC Wainwright & Co. | $15 → $21 | Maintains | Buy |
| 11/15/2022 | 206.51% | Chardan Capital | $15 → $16 | Maintains | Buy |
| 11/01/2022 | 91.57% | B. Riley Securities | → $10 | Initiates Coverage On | → Buy |
| 08/12/2021 | 187.36% | HC Wainwright & Co. | $20 → $15 | Maintains | Buy |
| 06/28/2021 | 378.93% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
| 06/09/2021 | 187.36% | Chardan Capital | $11 → $15 | Maintains | Buy |
| 06/02/2021 | 283.14% | HC Wainwright & Co. | $8 → $20 | Maintains | Buy |
| 05/20/2021 | 110.73% | Chardan Capital | $10 → $11 | Maintains | Buy |
| 03/19/2021 | 53.26% | HC Wainwright & Co. | $6 → $8 | Maintains | Buy |
| 05/27/2020 | -23.37% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/30/2020 | 34.1% | HC Wainwright & Co. | → $7 | Downgrades | Buy → Neutral |
| 11/05/2019 | 34.1% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 10/24/2019 | 91.57% | Chardan Capital | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/27/2023 | 302.3% | HC Wainwright公司 | →$21 | 重申 | 購買→購買 |
| 09/20/2023 | 302.3% | HC Wainwright公司 | →$21 | 重申 | 購買→購買 |
| 2023年08月14日 | 302.3% | HC Wainwright公司 | $21→$21 | 重申 | 購買→購買 |
| 06/06/2023 | 302.3% | HC Wainwright公司 | →$21 | 重申 | 購買→購買 |
| 2023年05月26日 | 359.77% | 奧本海默 | →$24 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月26日 | 302.3% | HC Wainwright公司 | →$21 | 重申 | 購買→購買 |
| 2023年05月16日 | 359.77% | 奧本海默 | →$24 | 重申 | →跑贏大盤 |
| 04/24/2023 | 302.3% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 03/30/2023 | 302.3% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 03/29/2023 | 129.89% | B.萊利證券 | →$12 | 重申 | →購買 |
| 03/28/2023 | 302.3% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 02/28/2023 | 302.3% | HC Wainwright公司 | →$21 | 維護 | 買 |
| 01/03/2023 | 302.3% | HC Wainwright公司 | $15→$21 | 維護 | 買 |
| 2022年11月15日 | 206.51% | 查爾丹資本 | $15→$16 | 維護 | 買 |
| 11/01/2022 | 91.57% | B.萊利證券 | →$10 | 開始承保 | →購買 |
| 2021/08/12 | 187.36% | HC Wainwright公司 | $20→$15 | 維護 | 買 |
| 2021/06/28 | 378.93% | 康託·菲茨傑拉德 | →$25 | 開始承保 | →超重 |
| 06/09/2021 | 187.36% | 查爾丹資本 | $11→$15 | 維護 | 買 |
| 06/02/2021 | 283.14% | HC Wainwright公司 | $8→$20 | 維護 | 買 |
| 05/20/2021 | 110.73% | 查爾丹資本 | $10→$11 | 維護 | 買 |
| 03/19/2021 | 53.26% | HC Wainwright公司 | $6→$8 | 維護 | 買 |
| 05/27/2020 | -23.37% | 聯盟全球合作夥伴 | →$4 | 開始承保 | →購買 |
| 03/30/2020 | 34.1% | HC Wainwright公司 | →$7 | 評級下調 | 購買→中性 |
| 2019年11月05日 | 34.1% | HC Wainwright公司 | →$7 | 開始承保 | →購買 |
| 2019年10月24日 | 91.57% | 查爾丹資本 | →$10 | 開始承保 | →購買 |
What is the target price for PDS Biotechnology (PDSB)?
PDS Biotech(PDSB)的目標價格是多少？
The latest price target for PDS Biotechnology (NASDAQ: PDSB) was reported by HC Wainwright & Co. on September 27, 2023. The analyst firm set a price target for $21.00 expecting PDSB to rise to within 12 months (a possible 302.30% upside). 15 analyst firms have reported ratings in the last year.
納斯達克(代碼：PDSB)的最新目標價是由HC Wainwright&Co.於2023年9月27日報道的。這家分析公司將目標價定為21美元，預計PDSB將在12個月內上漲至(可能上漲302.30%)。過去一年，有15家分析公司公佈了評級。
What is the most recent analyst rating for PDS Biotechnology (PDSB)?
PDS Biotech(PDSB)的最新分析師評級是多少？
The latest analyst rating for PDS Biotechnology (NASDAQ: PDSB) was provided by HC Wainwright & Co., and PDS Biotechnology reiterated their buy rating.
PDS Biotech(納斯達克代碼：PDSB)的最新分析師評級由HC Wainwright&Co.提供，PDS Biotech重申其買入評級。
When is the next analyst rating going to be posted or updated for PDS Biotechnology (PDSB)?
PDS Biotech(PDSB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PDS Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PDS Biotechnology was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與PDS Biotech的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。PDS生物技術的上一次評級是在2023年9月27日提交的，所以你應該預計下一次評級將在2024年9月27日左右的某個時候提供。
Is the Analyst Rating PDS Biotechnology (PDSB) correct?
分析師對PDS Biotech(PDSB)的評級正確嗎？
While ratings are subjective and will change, the latest PDS Biotechnology (PDSB) rating was a reiterated with a price target of $0.00 to $21.00. The current price PDS Biotechnology (PDSB) is trading at is $5.22, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的PDS Biotech(PDSB)評級被重申，目標價在0.00美元至21.00美元之間。PDS Biotech(PDSB)目前的交易價格為5.22美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。